Search Results

Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company announced that it has granted AstraZeneca Plc a global online STARMAP® license.

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C.

Cardio Diagnostics Holdings, Inc, a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced a significant move to transform global cardiovascular health, by entering into a Supply and Distribution Agreement with one of India’s premier organizations, Aimil Ltd.

Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.

XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions.